title: Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
abstract: BACKGROUND
  In collaboration with the Canadian Immunization Monitoring Program Active (IMPACT), the National Microbiology Laboratory, the UK Health Protection Agency and Novartis Vaccines, we tested the potential of an investigational 4-component meningococcal B vaccine (4CMenB) to cover Canadian strains circulating from 2006 to 2009.
  
  
  METHODS
  IMPACT meningococcal surveillance is population based and includes over 50% of Canadian adults and children. All isolates were characterized by Meningococcal Antigen Typing System (MATS) and sequencing for factor H-binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisserial adhesin A (NadA).
  
  
  RESULTS
  In total, 157 isolates were tested. Overall, 4CMenB MATS predicted strain coverage was 66% (95% CI: 46-78%), with 26%, 29% and 11% of strains covered by one, two and three vaccine antigens, respectively. The coverage of each antigen was as follows: 13% PorA, 1% NadA, 52% fHbp and 51% NHBA. The majority of strains for clonal complex (cc) 41/44 and cc60 were covered by NHBA; the majority of strains for cc269 and cc32 were covered by fHbp and NHBA. Coverage for two prevalent strains (sequence type (ST)-269 and ST-154) was 95% and 100%, respectively.
  
  
  CONCLUSIONS
  4CMenB has the potential to protect against a significant proportion of Canadian invasive MenB strains.
authors.affiliation: Vaccine Evaluation Center, BC Children's Hospital and the University of British Columbia, Vancouver V5Z4H4, Canada. Electronic address: jbettinger@cfri.ca.
authors.forename: Julie A
authors.initials: JA
authors.lastname: Bettinger
authors.affiliation: Vaccine Evaluation Center, BC Children's Hospital and the University of British Columbia, Vancouver V5Z4H4, Canada.
authors.forename: David W
authors.initials: DW
authors.lastname: Scheifele
authors.affiliation: Canadian Center for Vaccinology, IWK Health Centre and Dalhousie University, Halifax B3K6R8, Canada.
authors.forename: Scott A
authors.initials: SA
authors.lastname: Halperin
authors.affiliation: Stollery Children's Hospital and University of Alberta, Edmonton T6G1C9, Canada.
authors.forename: Wendy
authors.initials: W
authors.lastname: Vaudry
authors.affiliation: Vaccine Evaluation Unit, Health Protection Agency, Manchester M13 9WZ, UK.
authors.forename: Jamie
authors.initials: J
authors.lastname: Findlow
authors.affiliation: Vaccine Evaluation Unit, Health Protection Agency, Manchester M13 9WZ, UK.
authors.forename: Ray
authors.initials: R
authors.lastname: Borrow
authors.affiliation: Novartis Vaccines, Siena 53100, Italy.
authors.forename: Duccio
authors.initials: D
authors.lastname: Medini
authors.affiliation: National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg R3E3R2, Canada.
authors.forename: Raymond
authors.initials: R
authors.lastname: Tsang
mesh_terms: D000942:Antigens, Bacterial / Q000276:immunology; D002170:Canada; D002648:Child; D002675:Child, Preschool; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000145:classification* / Q000235:genetics / Q000276:immunology*; D011159:Population Surveillance; D015995:Prevalence
chemical_list: D000942:Antigens, Bacterial; D022401:Meningococcal Vaccines
keywords: 4CMenB coverage; Invasive meningococcal disease; Meningitis; Meningococcal Antigen Typing System; Serogroup B vaccines